Risk adjusted net present value: What is the current valuation of Brii Biosciences’s Elebsiran?
The revenue for Elebsiran is expected to reach an annual total of $23 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Elebsiran Overview
Elebsiran (VIR-2218) is under development for the treatment of hepatitis B and D virus infections. It is administered through subcutaneous route and acts by targeting hepatitis B virus (HBV) genome including HBsAg. It is a siRNA therapeutic developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology.
Brii Biosciences Overview
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Brii Biosciences is a biotechnology company that develops and commercializes medicines to treat central nervous systems and infectious disease. It is investigating BRII-835 (VIR-2218) and BRII-179 (VBI-2601) against Hepatitis B virus; BRII-658 targeting multidrug-resistant TB (MDR-TB) mycobacteria; and BRII-636 (QPX-7728), BRII-672 (QPX-7831) and BRII-693 (QPX-9003) to treat infections caused due to multidrug-resistant gram-negative bacteria (MDR-GNB). The company is also evaluating BRII-732 and BRII-778 against human immunodeficiency virus (HIV); BRII-196 and BRII-198 targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); BRII-296 for paranoid personality disorder and major depressive disorder (MDD). The company has operations in China and the US. Brii Biosciences is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY51.6 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was CNY488.9 million in FY2022, compared to an operating loss of CNY4,189.9 million in FY2021. The net loss of the company was CNY484.3 million in FY2022, compared to a net loss of CNY4,163.9 million in FY2021.
For a complete picture of Elebsiran’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Source link
#Risk #adjusted #net #present #current #valuation #Brii #Biosciencess #Elebsiran
